Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24998101 | 1.00 | CCR8 (0.75) | CCR8 | |
| SCHEMBL30260252 | 0.91 | CCR8 (0.64) | CCR8 | |
| SCHEMBL24170888 | 0.91 | CCR8 (0.64) | CCR8 | |
| SCHEMBL24997776 | 0.88 | CCR8 (0.76) | CCR8 | |
| SCHEMBL30260259 | 0.88 | CCR8 (0.76) | CCR8 | |
| SCHEMBL25612650 | 0.87 | CCR8 (0.62) | CCR8 | |
| SCHEMBL24999099 | 0.86 | CCR8 (1.00) | CCR8 | |
| SCHEMBL30260380 | 0.86 | CCR8 (1.00) | CCR8 | |
| SCHEMBL24997826 | 0.86 | CCR8 (1.00) | CCR8 | |
| SCHEMBL24170133 | 0.86 | CCR8 (1.00) | CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175949-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | claimed |
| CN-115989223-A | Methods and compositions for targeting Tregs using CCR8 inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-12552753-B2 | Methods and compositions for targeting Tregs using CCR8 inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| CN-115989223-B | Methods and compositions for targeting Tregs using CCR8 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4175949-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| CN-115989223-A | Methods and compositions for targeting Tregs using CCR8 inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | CCR8 1/4885 |
| US-12552753-B2 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | CCR8 1/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | CCR8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.